A detailed history of State Street Corp transactions in Nautilus Biotechnology, Inc. stock. As of the latest transaction made, State Street Corp holds 932,931 shares of NAUT stock, worth $2.24 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
932,931
Previous 941,238 0.88%
Holding current value
$2.24 Million
Previous $2.2 Million 20.71%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.24 - $3.08 $18,607 - $25,585
-8,307 Reduced 0.88%
932,931 $2.66 Million
Q2 2024

Aug 14, 2024

BUY
$2.22 - $3.0 $7,081 - $9,570
3,190 Added 0.34%
941,238 $2.2 Million
Q1 2024

May 15, 2024

SELL
$2.41 - $3.18 $1,253 - $1,653
-520 Reduced 0.06%
938,048 $2.76 Million
Q4 2023

Feb 14, 2024

BUY
$2.34 - $3.39 $2,070 - $3,000
885 Added 0.09%
938,568 $2.81 Million
Q3 2023

Nov 14, 2023

BUY
$2.87 - $3.94 $4,373 - $6,004
1,524 Added 0.16%
937,683 $2.96 Million
Q2 2023

Aug 14, 2023

BUY
$2.21 - $4.52 $489,857 - $1 Million
221,655 Added 31.02%
936,159 $3.62 Million
Q1 2023

May 15, 2023

BUY
$1.67 - $2.77 $20,541 - $34,071
12,300 Added 1.75%
714,504 $1.98 Million
Q4 2022

Feb 14, 2023

BUY
$1.55 - $2.47 $77,312 - $123,201
49,879 Added 7.65%
702,204 $1.26 Million
Q3 2022

Nov 15, 2022

BUY
$1.96 - $3.13 $141,398 - $225,804
72,142 Added 12.43%
652,325 $1.38 Million
Q2 2022

Aug 15, 2022

BUY
$2.64 - $4.84 $1.04 Million - $1.91 Million
394,228 Added 212.0%
580,183 $1.56 Million
Q1 2022

May 16, 2022

BUY
$3.5 - $5.3 $30,642 - $46,401
8,755 Added 4.94%
185,955 $807,000
Q4 2021

Feb 14, 2022

BUY
$4.45 - $6.21 $86,775 - $121,095
19,500 Added 12.37%
177,200 $918,000
Q3 2021

Nov 15, 2021

BUY
$6.14 - $10.1 $968,278 - $1.59 Million
157,700 New
157,700 $968,000

Others Institutions Holding NAUT

About Nautilus Biotechnology, Inc.


  • Ticker NAUT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,663,000
  • Market Cap $299M
  • Description
  • Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was found...
More about NAUT
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.